Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2106 in advanced metastatic ovarian cancer
NCT00291837Phase 2Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Nov 2004
- Primary completion
- Jun 2006
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of polyglutamate camptothecin in ovarian cancer, sponsored by CTI BioPharma Corp. Primary endpoint: Response Rate. Started Nov 2004; status: completed.
02
Drugs
polyglutamate camptothecin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00291837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291837.